Figure 6

miR-19b reduces intestinal inflammation.

(a), DAI indices were monitored daily after pre-miR-19b treatment (n = 8 mice per group;^**p = 0.006, TNBS group vs. PEI+pre-miR19b group; ^*p = 0.024, PEI group vs. PEI+pre-miR-19b group;^*p = 0.027, PEI+pre-scramble group vs. PEI+pre-miR-19b group). (b), Colons were removed for macroscopic observation three days after TNBS treatment. (c), Colon sections from control mice or TNBS+pre-miR-19b-treated mice were examined by H&E staining (Top panel: magnification, 100×, scale bars = 100 μm; Bottom panel: magnification, 200×, scale bars = 50 μm). (d), Histopathological scores were calculated according to H&E staining (n = 8 mice per group;^***p = 0.0000256, TNBS group vs. PEI+pre-miR19b group; ^**p = 0.003448, PEI group vs. PEI+pre-miR-19b group; ^**p = 0.007246, PEI+pre-scramble group vs. PEI+pre-miR-19b group). (e), Immunofluoresence staining to determine miRNA precursor localization after intracolonic administration of the Cy3-labeled pre-miR-19b/PEI complex. Red, miR-19b-precusor; green, pan-cytokeratin (PCK); blue, DAPI nuclear staining (magnification, 400×). All values are expressed as the mean±SEM.